Efficacy and Safety of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase 3, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimized Study in Europe

Friday, October 21, 2011

David R. Coghill, M.D., F.R.C.Psych., M.B.Ch.B., Centre for Neuroscience, Dundee, Scotland

Tobias Banaschewski, M.D., Ph.D., Department of Child and Adolescent Psychiatry and Psychotherapy, Mannheim, Germany

Michel L. Lecendreux, M.D., Pediatric Sleep Center, Paris, France

Cesar A. Soutullo, M.D., Ph.D., University of Navarra Clinic, Pamplona, Spain

Mats Johnson, M.D., Child Neuropsychiatry Unit, Göteborg, Sweden

Colleen S. Anderson, B.A., Shire Development Inc, Wayne, PA

Richard Civil, M.D., Clinical Development and Medical Affairs, Shire Pharmaceuticals Inc, Wayne, PA

C. Nicholas Higgins, B.S., Clinical Programs, Shire Development Inc, Wayne, PA

Andrew Lyne, M.S.C., C.Stat., Shire Pharmaceuticals Inc, Basingstoke, United Kingdom

Liza A. Squires, M.D., Shire Pharmaceuticals Inc, Wayne, PA


Please note that this schedule is subject to change. The Program Book distributed at the Annual Meeting will have final information on dates, times, and speakers for each presentation.

New Research Poster Presentation 4.10 Efficacy and Safety of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase 3, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimized Study in Europe